445 filings
Page 7 of 23
6-K
r8pmzq3 6yzf0pq
25 Feb 22
Mesoblast Prepares for Resubmission of Biologics License Application
7:46pm
6-K
zg6xjb9p3i
25 Feb 22
Provided to the Asx Under Listing Rule 4.2A
12:00am
6-K
kua8ixnv3ujef
22 Feb 22
Current report (foreign)
7:37am
6-K
9l7cnyikh
4 Feb 22
Mesoblast Appoints DR Eric Rose As Chief Medical Officer
6:01am
6-K
f7iyue0
1 Feb 22
Appendix 4C Quarterly Activity Report
12:00am
6-K
fgh8n068f o2aeac
27 Jan 22
Mesoblast to Participate In Edison Group’s Global Healthcare “Open House” Virtual Conference from January 25-27TH, 2022
9:20pm
F-3ASR
dxitnef
24 Jan 22
Automatic shelf registration (foreign)
6:12am
6-K
ckvn9gw oep
21 Jan 22
Current report (foreign)
12:00am
SC 13G/A
a8kyea2i
19 Jan 22
MESOBLAST / M&G Alternatives Investment Management ownership change
8:28am
6-K
phxdev8okro3 6g
19 Jan 22
36-Month Results of Phase 3 Trial in Chronic Low Back Pain Presented at 2022 Biotech Showcase
12:00am
6-K
0nr znz8j
3 Jan 22
Mesoblast Provides Update Following Meeting with Fda’s Otat on Remestemcel-l for Children with Acute Graft Versus Host Disease
6:02am
S-8
zqog28ok47ihhernh304
23 Dec 21
Registration of securities for employees
6:10am
6-K
qx0hd26bfx 820f8d
17 Dec 21
Fda’s Otat In Agreement with 12-MONTH Reduction In Pain As Primary Endpoint for Chronic Low Back Pain Program
12:00am
6-K
61487b66
14 Dec 21
Update on Novartis Agreement
6:03am
6-K
ccj4anmq3u u3rv73nh
7 Dec 21
Current report (foreign)
6:12am
6-K
j29dkg wss9hym2
2 Dec 21
Current report (foreign)
12:00am
6-K
im268rxm lb6uw9bvd
26 Nov 21
Current report (foreign)
12:00am
6-K
1hujam 5y466gki
24 Nov 21
Current report (foreign)
6:04am
6-K
unrslz 6b5te
16 Nov 21
Late Breaking Presentation at American Heart Association Annual Meeting of Landmark Phase 3 Trial of Rexlemestrocel-l In Chronic Heart Failure
7:13am
6-K
8fs23s
9 Nov 21
Current report (foreign)
6:09am